Acalabrutinib – CALQUENCE® (USA)
According to the NCI website Acalabrutinib orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
Indicated according to Chemocare for:
- The treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- The treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
More Information in English:
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com